| HOME >> MEDICINE >> TECHNOLOGY |
6.3.3 CV Portfolio 34
6.4 Daiichi Sankyo Company, Limited 34
6.4.1 Overview 34
6.4.2 Business Description 34
6.4.3 CV Portfolio 35
6.4.4 Atrial Fibrillation product portfolio 35
6.5 Boehringer Ingelheim 36
6.5.1 Overview 36
6.5.2 Business Description 36
6.5.3 CV Portfolio 36
6.5.4 Atrial Fibrillation Product Portfolio 37
6.6 Procter and Gamble 37
6.6.1 Overview 37
6.6.2 Business Description 37
6.6.3 CV Portfolio 38
6.6.4 Atrial Fibrillation Product Portfolio 38
6.7 Bayer Healthcare 39
6.7.1 Overview 39
6.7.2 Business Description 39
6.7.3 CV Portfolio 39
6.7.4 Atrial Fibrillation Product Portfolio 39
7 Atrial Fibrillation Market: Appendix 41
7.1 Definitions 41
7.2 Acronyms 41
7.3 Research Methodology 42
7.3.1 Coverage 43
7.3.2 Secondary Research 43
7.3.3 Forecasting 43
7.3.4 Primary Research 46
7.3.5 Expert Panels 46
7.4 Contact Us 46
7.5 Disclaimer 46
7.6 Sources 47
1.1 List of Tables
Table 1: Global Atrial Fibrillation Market Revenues, 2001-2009 7
Table 2: Global Atrial Fibrillation Market Forecast, 2009-2016 8
Table 3: Strategic Competitor Assessment of the Major Marketed Products in Atrial Fibrillation, 2010 11
Table 4: A summary of Key Phase III clinical trials for Multaq 13
Table 5: Major Marketed Products in the Atrial Fibrillation Market, 2010 17
Table 6: Atrial Fibrillation Therapeutics –Promising Drugs Under Clinical Development, 2010 20
Table 7: Clinical study details on ROCKET-AF with Xarelto 21
T
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |